Patents by Inventor Usama Ahmed Fahmy

Usama Ahmed Fahmy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Grasping prostate morcellator
    Patent number: 11457943
    Abstract: A prostate grasping morcellator device and a method of morcellating prostate tissue are described. The prostate grasping morcellator device includes a handpiece portion including a motor which rotates an internal sheath in an external sheath of a rod. The rod is connected to a second end of the handpiece portion. The prostate grasping morcellator device includes one or more retractable grasping nails connected to an end of the rod. The end is distal to the second end of the handpiece portion. The prostate grasping morcellator device includes a control button to control movement of the retractable grasping nails. The control button is mounted adjacent to the second end of the handpiece portion. The prostate grasping morcellator device includes one or more blades, rotated by the motor to morcellate tissue.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 4, 2022
    Assignee: King Abdulaziz University
    Inventors: Usama Ahmed Fahmy, Nabil Abdulhafiz Alhakamy, Osama Abdulhakim Ali Ahmed, Ashraf Bahi Eldin Abdel Naiem, Basma Ghazi Eid, Omar Ahmed Fahmy
  • Method of treating chronic hepatic fibrosis comprising administration of zeinmersome nanocarriers
    Patent number: 11013689
    Abstract: Zeinmersomes (ZMS) comprising zein, a phospholipid and a PEG-polymer are formulated to encapsulate a drug of interest. Olmesartan medoxomil (OM) is encapsulated in the ZMS (OM-ZMS) for oral administration and taken up by the liver where OM diffuses from the ZMS nanocarrier. OM concentrations in liver were at least 8 times higher than that measured in plasma. Established fibrosis was reversed in a thioacetamide-induced rat model of human chronic hepatic fibrosis. The OM-ZMS provides a hepatic drug delivery system that reduces the potential of side-effects caused by OM, including OM-associated sprue-like enteropathy, to treat chronic hepatic fibrosis and associated duodenal changes.
    Type: Grant
    Filed: December 21, 2020
    Date of Patent: May 25, 2021
    Assignee: King Abdulaziz University
    Inventors: Hussam Aly Sayed Murad, Osama Abdelhakim Aly Ahmed, Usama Ahmed Fahmy Ahmed
  • Zeinmersome nanocarriers for drug delivery to the liver
    Patent number: 10905651
    Abstract: Zeinmersomes (ZMS) comprising zein, a phospholipid and a PEG-polymer are formulated to encapsulate a drug of interest. Olmesartan medoxomil (OM) is encapsulated in the ZMS (OM-ZMS) for oral administration and taken up by the liver where OM diffuses from the ZMS nanocarrier. OM concentrations in liver were at least 8 times higher than that measured in plasma. Established fibrosis was reversed in a thioacetamide-induced rat model of human chronic hepatic fibrosis. The OM-ZMS provides a hepatic drug delivery system that reduces the potential of side-effects caused by OM, including OM-associated sprue-like enteropathy, to treat chronic hepatic fibrosis and associated duodenal changes.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: February 2, 2021
    Assignee: King Abdulaziz University
    Inventors: Hussam Aly Sayed Murad, Osama Abdelhakim Aly Ahmed, Usama Ahmed Fahmy Ahmed